Search Results
Aug 10, 2026, 08:30 ET Theravance Biopharma, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update
DUBLIN, Aug. 10, 2026 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today reported financial and operational results for the second quarter of 2026.
More news about: Theravance Biopharma, Inc.
Jul 09, 2026, 19:09 ET Are TBPH, IRDM, LCII, PATK Obtaining Fair Deals for their Shareholders?
multimedia:https://www.prnewswire.com/news-releases/are-tbph-irdm-lcii-patk-obtaining-fair-deals-for-their-shareholders-302822279.htmlSOURCE
More news about: Halper Sadeh LLP
Jul 09, 2026, 14:43 ET $HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--TBPH, IRDM, LCII, and PATK
TBPH) related to its sale to Zymeworks Inc. Under the terms of the proposed transaction, Theravance shareholders are expected to receive (i) $176.00
More news about: Monteverde & Associates PC
Jun 29, 2026, 13:59 ET Are IRDM, TBPH, SYNA, TECH Obtaining Fair Deals for their Shareholders?
multimedia:https://www.prnewswire.com/news-releases/are-irdm-tbph-syna-tech-obtaining-fair-deals-for-their-shareholders-302813409.htmlSOURCE
More news about: Halper Sadeh LLP
Jun 29, 2026, 13:36 ET $HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Theravance Biopharma, Inc. (NASDAQ: TBPH)
TBPH) related to its sale to Zymeworks Inc. Under the terms of the proposed transaction, Theravance shareholders are expected to receive (i) $176.00
More news about: Monteverde & Associates PC
Jun 29, 2026, 10:02 ET Shareholder Alert: Ademi LLP investigates whether Theravance Biopharma, Inc. is obtaining a Fair Price for Public Shareholders
MILWAUKEE, June 29, 2026 /PRNewswire/ -- Ademi LLP is investigating Theravance Biopharma (NASDAQ: TBPH) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Zymeworks.
More news about: Ademi LLP
Jun 29, 2026, 06:00 ET THERAVANCE BIOPHARMA ENTERS INTO DEFINITIVE AGREEMENT TO BE ACQUIRED BY ZYMEWORKS FOR $17.00 PER SHARE IN CASH PLUS A CONTINGENT VALUE RIGHT
DUBLIN, June 29, 2026 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (Nasdaq: TBPH) today announced that it has entered into a definitive agreement pursuant to which Zymeworks Inc. will acquire the Company for $17.00 per share in cash,
More news about: Theravance Biopharma, Inc.
May 07, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc. - TBPH
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Theravance Biopharma, Inc. ("Theravance" or the "Company") (NASDAQ: TBPH). Such investors are advised to contact Danielle Peyton at [email protected] or
More news about: Pomerantz LLP
May 07, 2026, 08:30 ET Theravance Biopharma, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update
DUBLIN, May 7, 2026 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today reported financial and operational results for the first quarter of 2026.
More news about: Theravance Biopharma, Inc.
Apr 30, 2026, 22:40 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc. - TBPH
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Theravance Biopharma, Inc. ("Theravance" or the "Company") (NASDAQ: TBPH). Such investors are advised to contact Danielle Peyton at [email protected] or
More news about: Pomerantz LLP
Apr 16, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc. - TBPH
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Theravance Biopharma, Inc. ("Theravance" or the "Company") (NASDAQ: TBPH). Such investors are advised to contact Danielle Peyton at [email protected] or
More news about: Pomerantz LLP
Apr 15, 2026, 09:00 ET TBPH: Reported $22M in Operating Expenses While Advancing Trial Enrollment -- LEVI & KORSINSKY, LLP Investigates
NEW YORK, April 15, 2026 /PRNewswire/ -- Theravance Biopharma (NASDAQ: TBPH) shareholders lost approximately 26% of their investment on March 3, 2026, when the Company disclosed that its Phase 3 CYPRESS trial failed. Shareholders
More news about: Levi & Korsinsky, LLP
Apr 09, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc. - TBPH
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Theravance Biopharma, Inc. ("Theravance" or the "Company") (NASDAQ: TBPH). Such investors are advised to contact Danielle Peyton at [email protected] or
More news about: Pomerantz LLP
Apr 01, 2026, 09:00 ET TBPH: Reported $22M in Operating Expenses While Advancing Trial Enrollment -- LEVI & KORSINSKY, LLP Investigates
NEW YORK, April 1, 2026 /PRNewswire/ -- Theravance Biopharma (NASDAQ: TBPH) shareholders lost approximately 26% of their investment on March 3, 2026, when the Company disclosed that its Phase 3 CYPRESS trial failed. Shareholders
More news about: Levi & Korsinsky, LLP
Mar 25, 2026, 09:00 ET TBPH: Reported $22M in Operating Expenses While Advancing Trial Enrollment -- LEVI & KORSINSKY, LLP Investigates
NEW YORK, March 25, 2026 /PRNewswire/ -- Theravance Biopharma (NASDAQ: TBPH) shareholders lost approximately 26% of their investment on March 3, 2026, when the Company disclosed that its Phase 3 CYPRESS trial failed. Shareholders
More news about: Levi & Korsinsky, LLP
Mar 19, 2026, 08:30 ET Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
DUBLIN, March 19, 2026 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today reported financial and operational results for the fourth quarter and full year of 2025.
More news about: Theravance Biopharma, Inc.
Mar 18, 2026, 10:00 ET TBPH Guided for $75M in Milestones While Trial Risk Went Unquantified -- LEVI & KORSINSKY, LLP
FailNEW YORK, March 18, 2026 /PRNewswire/ -- Theravance Biopharma (NASDAQ: TBPH) shareholders lost approximately 26% when shares collapsed on March 3, 2026. In the quarters leading up to that drop, management reaffirmed financial
More news about: Levi & Korsinsky, LLP
Mar 11, 2026, 09:00 ET TBPH: Reported $22M in Operating Expenses While Advancing Trial Enrollment -- LEVI & KORSINSKY, LLP Investigates
EnrollmentNEW YORK, March 11, 2026 /PRNewswire/ -- Theravance Biopharma (NASDAQ: TBPH) shareholders lost approximately 26% of their investment on March 3, 2026, when the Company disclosed that its Phase 3 CYPRESS trial failed. Shareholders
More news about: Levi & Korsinsky, LLP
Mar 03, 2026, 08:30 ET Theravance Biopharma Reports Phase 3 CYPRESS Study Did Not Meet Primary Endpoint; Board Accelerates Strategic Review and Announces Cost Reduction Actions
DUBLIN, March 3, 2026 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced topline results from the Phase 3 CYPRESS study evaluating the efficacy and safety of ampreloxetine in patients with symptomatic neurogenic
More news about: Theravance Biopharma, Inc.
Nov 20, 2025, 11:00 ET Theravance Biopharma to Host Virtual KOL Investor Event to Review Ampreloxetine Phase 3 Clinical Development Program, Ahead of Topline Data in Q1 2026, on December 8, 2025
DUBLIN, Nov. 20, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) today announced that it will host a virtual key opinion leader (KOL) investor event on Monday, December 8, 2025 at 10:30 AM ET. To register, click
More news about: Theravance Biopharma, Inc.
Nov 19, 2025, 06:00 ET Theravance Biopharma to Participate in Upcoming Investor Conferences
DUBLIN, Nov. 19, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) today announced that management will participate in the following investor conferences in December 2025:
More news about: Theravance Biopharma, Inc.
Nov 10, 2025, 16:05 ET Theravance Biopharma, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update
DUBLIN, Nov. 10, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today reported financial and operational results for the third quarter of 2025.
More news about: Theravance Biopharma, Inc.
Oct 29, 2025, 06:00 ET Theravance Biopharma to Present Data on Ampreloxetine at the 36th International Symposium on The Autonomic Nervous System
DUBLIN, Oct. 29, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) today announced that it will be participating at the 36th International Symposium on the Autonomic Nervous System, organized by the American
More news about: Theravance Biopharma, Inc.
Oct 27, 2025, 06:00 ET Theravance Biopharma to Report Third Quarter 2025 Financial Results on November 10, 2025
DUBLIN, Oct. 27, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its third quarter 2025 financial results and provide a business update after market close on Monday, November 10, 2025. An accompanying
More news about: Theravance Biopharma, Inc.
Oct 14, 2025, 06:00 ET Theravance Biopharma to Present New Analyses Highlighting YUPELRI® (revefenacin) Outcomes in COPD at the 2025 CHEST Annual Meeting
DUBLIN, Oct. 14, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH), today announced that it will be presenting two rapid-fire presentations at CHEST 2025, the annual meeting of the American College of Chest Physicians
More news about: Theravance Biopharma, Inc.